Year None2022202120202019201820172016 May 11, 2022 Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting Go to May 2, 2022 Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study Go to April 27, 2022 Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Go to April 8, 2022 Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting Go to April 8, 2022 Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting Go to March 10, 2022 Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference Go to Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
May 11, 2022 Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting Go to
May 2, 2022 Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study Go to
April 27, 2022 Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Go to
April 8, 2022 Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting Go to
April 8, 2022 Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting Go to
March 10, 2022 Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference Go to
